2005 Market Analysis provides a Unique Examination of Four Key Oncology Therapy Areas.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c24155) has announced the addition of Cancer Drug Discoveries: what the future holds to their offering

E[acute accent]Understand the prospects for this US$24 billion market.

E[acute accent]Unique market share and sales forecasts by product to 2012. A comprehensive examination of four major oncology therapy areas. Critical SWOT analyses of current and upcoming products. E[acute accent]This 325+ page market analysis provides a unique examination of four key oncology therapy areas:

E[acute accent]Breast Cancer

E[acute accent]Focusing on the changes in the gold standard, the impact of novel therapies on treatment and the new drugs in development.

E[acute accent]Non-Small Cell Lung Cancer 

E[acute accent]Focusing on the launch of novel therapies into the arena: are they dramatically changing the way NSCLC is treated?

E[acute accent]Colorectal Cancer 

E[acute accent]Focusing on the evolution of new treatment regimes, the development of new formulations and advances in cancer vaccines.

E[acute accent]Prostate Cancer 

E[acute accent]Focusing on current hormonal therapies, the treatment of HRPCA and improvements in screening.

E[acute accent]For each therapy area the report provides:

E[acute accent]Comprehensive Overview

E[acute accent]Patient statistics

E[acute accent]- Incidence;

E[acute accent]- Diagnosis and treatment rates.

E[acute accent]Growth drivers

E[acute accent]- Risk factors (genetics, age, sex etc);

E[acute accent]- Stage of the disease;

E[acute accent]- Medical guidelines;

E[acute accent]- Unmet clinical need;

E[acute accent]- Screening programmes.

E[acute accent]Current treatments

E[acute accent]- SWOT of drugs used and companies involved;

E[acute accent]- Summary of recent ASCO data (May 2005)

E[acute accent]- Highlight where and why there is still an unmet clinical need;

E[acute accent]- Sales forecasts by product 2004-2012.

E[acute accent]Drugs in Phase II/III development

E[acute accent]- Focus on new classes of drugs and companies involved;

E[acute accent]- Sales forecasts by product (year of launch to 2012).

E[acute accent]An overview of the value of the oncology market

E[acute accent]- Global sales;

E[acute accent]- Sales growth to 2012.

E[acute accent]Overall conclusions

E[acute accent]- A summary of the areas of unmet clinical need and growth opportunities;

E[acute accent]- Who the major players are now and in the future.

E[acute accent]For more information visit http://www.researchandmarkets.com/reports/c24155